Table I.
Detailed clinical characteristics of patients with thymoma enrolled in the present study.
| Masaoka-Koga stage | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO type | Patients, n | F/M, n | Age, years | I | II | III | IV | MG, n (%) | Other AID, n (%) | Recurrence, n (%) | Synchronous malignancy, n (%) |
| Type A | 15 | 5/10 | 55.3±13.1 | 13 | 2 | 0 | 0 | 11 (73) | 0 | 0 | 3 (20) |
| Type B1 | 19 | 9/10 | 52.2±15.0 | 11 | 4 | 4 | 0 | 13 (68) | 1 (5) | 0 | 0 |
| Type B2 | 41 | 26/15 | 56.9±14.0 | 13 | 18 | 2 | 8 | 26 (63) | 3 (7) | 5 (12) | 3 (7) |
| Type B3 | 37 | 14/23 | 52.1±14.1 | 4 | 17 | 11 | 6 | 19 (51) | 5 (14) | 4 (10) | 4 (11) |
| Total | 112 | 54/58 | 54.3±14.2 | 41 | 39 | 16 | 14 | 69 (62) | 9 (8) | 9 (8) | 10 (9) |
Age is presented as the mean ± SD. F, female; M, male; AID, autoimmune disorder; WHO, World Health Organization; MG, myasthenia gravis.